Latest event summaries
Event summaries combining transcripts, slides, and related documents. Updated as new events are published.
- FY26 saw 15% AUM growth, net profit of ₹65,488 lakh, and strong asset quality.AAVAS
Q4 25/26 - Q1 2026 featured strong data center progress, a $200M credit facility, and a $114M net loss.CIFR
Q1 2026 - Aficamten met all primary and key secondary endpoints in non-obstructive HCM Phase 3 trial.CYTK
Study result - Phase 1b trial for AKY-2519 in mCRPC initiated, targeting broad solid tumor indications.AKTS
Study update - Proxy seeks approval for director, auditor, stock issuance, and new equity plan; board recommends FOR.FBLG
Proxy filing - Q1 2026 revenue up 22%, AI ARR up 221%, and FY guidance raised with major expansion.DOCN
Q1 2026 - Elegrobart met all primary and key secondary endpoints in chronic TED, enabling a 2027 BLA filing.VRDN
Study result - Transocean plans to acquire Valaris, pending regulatory and shareholder approval.VAL
Proxy filing - Key votes include director election, auditor ratification, equity plan, and share issuance.FBLGProxy filing
- Revenue up 107% to $3.5M, net loss $12.6M, backlog $17.3M, 2026 guidance reaffirmed.PDYN
Q1 2026 - Q1 2026 revenue rose to $60.1M on IMCIVREE's U.S. launch, with global expansion underway.RYTM
Q1 2026 - Business combination, Nasdaq debut, and expanded quantum testbed drive strategic progress.HQ
Q1 2026 - Q1 2026 revenue surged 45% year-over-year, but net loss widened as investments grew.EVGO
Q1 2026 - AXPAXLI's Phase 3 success in wet AMD drives NDA plans amid rising R&D costs and strong cash position.OCUL
Q1 2026 - Q1 2026 revenue surged 28% to $392.9M, but acquisition costs led to a $(66.5)M net loss.ALKS
Q1 2026 - Revenue up 17.3%, adjusted EBITDA rose, net loss widened, and 2026 guidance was raised.FWRG
Q1 2026